Search Results - "Miksad, R."

Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: a Markov decision analysis by de Geus, S.W.L, Evans, D.B, Bliss, L.A, Eskander, M.F, Smith, J.K, Wolff, R.A, Miksad, R.A, Weinstein, M.C, Tseng, J.F

“…Abstract Background Neoadjuvant therapy is gaining acceptance as a valid treatment option for borderline resectable pancreatic cancer; however, its value for…”
Get full text

Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) by Miksad, R., Cicin, I., Chen, Y., Klumpen, H., Kim, S., Lin, Z., Youkstetter, J., Sen, S., Cheng, A., Meyer, T., Kelley, R., Abou-Alfa, G.

Get full text

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics by Ahn, D., Barzi, A., Miksad, R.A., Surinach, A., Corvino, F.A., Valderrama, A., Mamlouk, K., Pulgar, S., Bekaii-Saab, T.

Get full text

Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer by Kovtun, K, Moser, J.A, Callery, M, Kent, T, Tseng, J, Miksad, R, Bullock, A, Schlechter, B, Mahadevan, A

Get full text

Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet by Kamo, N., Dandapani, S.V., Miksad, R.A., Houlihan, M.J., Kaplan, I., Regan, M., Greenfield, T.K., Sanda, M.G.

“…Patients’ perspectives provide valuable information on quality of care. This study evaluates the feasibility and validity of Internet administration of Service…”
Get full text

A genomic case study of mixed fibrolamellar hepatocellular carcinoma by Griffith, O.L., Griffith, M., Krysiak, K., Magrini, V., Ramu, A., Skidmore, Z.L., Kunisaki, J., Austin, R., McGrath, S., Zhang, J., Demeter, R., Graves, T., Eldred, J.M., Walker, J., Larson, D.E., Maher, C.A., Lin, Y., Chapman, W., Mahadevan, A., Miksad, R., Nasser, I., Hanto, D.W., Mardis, E.R.

“…Mixed fibrolamellar hepatocellular carcinoma (mFL-HCC) is a rare liver tumor defined by the presence of both pure FL-HCC and conventional HCC components,…”
Get full text

Tumor response to a new, small diameter drug-eluting embolic in hepatocellular carcinoma by Justaniah, A.I, Ahmed, M, Brennan, I, Sarwar, A, Brook, O.R, Miksad, R, Faintuch, S

Get full text

Stereotactic Body Radiation Therapy for Unresectable Large and Multiple Hepatocellular Carcinoma by Mahadevan, A, Curry, M, Lake-Bakaar, B, Evenson, A, Bullock, A, Buchbinder, E, Miksad, R

Get full text

Superselective vs. lobar transarterial chemoembolization – incidence and clinical significance of non-targeted embolization by Brook, O.R, Brook, A, Ahmed, M, Brennan, I, Miksad, R, Bullock, A, Buchbinder, E, Rojan, A, Sacks, B, Faintuch, S

Get full text

Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria by Jahn, B., Rochau, U., Kurzthaler, C., Hubalek, M., Miksad, R., Sroczynski, G., Paulden, M., Kluibenschädl, M., Krahn, M., Siebert, U.

“…A Breast Cancer Outcomes model was developed at the ONCOTYROL research center to evaluate personalized test-treatment strategies in Austria. The goal was to…”
Get full text

1558PBiomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) by Cohen, A B, Neri, B D A P, Adamson, B J S, Scanlon, C M, Gross, C, Meropol, N J, Miksad, R A

“…Abstract Background Risk models for NSCLC have identified age as a prognostic factor, but the relevance of molecular biomarkers to age-related outcomes is…”
Get full text

O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) by Miksad, R, Cicin, I, Chen, Y, Klumpen, H, Kim, S, Lin, Z, Youkstetter, J, Sen, S, Cheng, A, Meyer, T, Kelley, R, Abou-Alfa, G

Get full text

735PReal-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics by Ahn, D, Barzi, A, Miksad, R A, Surinach, A, Corvino, F A, Valderrama, A, Mamlouk, K, Pulgar, S, Bekaii-Saab, T

Get full text

Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) by Chan, S.L., Miksad, R., Cicin, I., Chen, Y., Klumpen, H.J., Kim, S., Lin, Z.Z., Youkstetter, J., Sen, S., Cheng, A.-L., El-Khoueiry, A.B., Meyer, T., Kelley, R.K., Abou-Alfa, G.K.

Get full text

4:33 PM, Abstract No. 143 - Tumor response to a new, small diameter drug-eluting embolic in hepatocellular carcinoma by Justaniah, A.I., Ahmed, M., Brennan, I., Sarwar, A., Brook, O.R., Miksad, R., Faintuch, S.

Get full text

Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC) by Eads, J., Stein, S., El-Khoueiry, A., Manji, G., Abrams, T., Khorana, A.A., Miksad, R., Mahalingam, D., Sirard, C., Zhu, A.X., Goyal, L.

Get full text

9:12 AM Abstract No. 88 - Superselective vs. lobar transarterial chemoembolization – incidence and clinical significance of non-targeted embolization by Brook, O.R., Brook, A., Ahmed, M., Brennan, I., Miksad, R., Bullock, A., Buchbinder, E., Rojan, A., Sacks, B., Faintuch, S.

“…To determine incidence and clinical significance of non-targeted embolization (NTE) after superselective (S-TACE) and lobar transarterial chemoembolization…”
Get full text

A technique to measure wavenumber mismatch between quadratically interacting modes by HAJJ, M. R, DAVILA, J. B, MIKSAD, R. W, POWERS, E. J

“…Abstract nonlinear energy cascade by means of three-wave resonant interactions is a characteristic feature of transitioning and turbulent flows. Resonant…”
Get full text

Adaptive second-order Volterra filtering and its application to second-order drift phenomena by Kiho Kim, Sung Bae Kim, Powers, E.J., Miksad, R.W., Fischer, F.J.

“…This paper presents an adaptive second-order Volterra filter and its application to model-test data of a prototype tension leg platform (TLP). The…”
Get full text

Progression-free survival as a surrogate endpoint in advanced breast cancer by Miksad, Rebecca A, Zietemann, Vera, Gothe, Raffaella, Schwarzer, Ruth, Conrads-Frank, Annette, Schnell-Inderst, Petra, Stollenwerk, Björn, Siebert, Uwe

“…Progression-free survival (PFS) has not been validated as a surrogate endpoint for overall survival (OS) for anthracycline (A) and taxane-based (T)…”
Get more information